CEO Stephen Hurly told BioWorld Today that Viventia Bio Inc.'s bid to lift antibody-drug conjugates (ADCs) "to the next level" in oncology powered a merger deal with Eleven Biotherapeutics Inc., a peer in protein engineering that's had some stumbles developing ophthalmology therapies.